Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (111-120 of 209) with videos related to

Pageof 21
Sort By:
Photochemistry and Photobiology|December 30, 2004
Effects of ultraviolet B exposure on the expression of proliferating cell nuclear antigen in murine skinJulian O Moore, Sapna R Palep, Rao N Saladi, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)Andrew Blauvelt, Kim A Papp, Mark G Lebwohl, et al.
Archives of Dermatological Research|August 20, 2018
Efficacy and safety of secukinumab treatment in adults with extensive alopecia areataEmma Guttman-Yassky, John K Nia, Peter W Hashim, et al.
Journal of the American Academy of Dermatology|April 19, 2011
Psoriasis in the elderly: from the Medical Board of the National Psoriasis FoundationIvan S Grozdev, Abby S Van Voorhees, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Journal of the American Academy of Dermatology|October 9, 2009
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis FoundationAmylynne J Frankel, Abby S Van Voorhees, Sylvia Hsu, et al.
Dermatology (Basel, Switzerland)|February 16, 2023
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis FlaresSiew Eng Choon, Mark G Lebwohl, Hamida Turki, et al.
Journal of the American Academy of Dermatology|April 4, 2018
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trialsLinda Stein Gold, Mark G Lebwohl, Jeffrey L Sugarman, et al.
Clinical and Experimental Dermatology|August 14, 2024
Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims dataAndreas Pinter, Ahmed M Soliman, Karina C Manz, et al.
Journal of the American Academy of Dermatology|September 30, 2019
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Pageof 21

Showing results (111-120 of 209) with videos related to

Sort By:
Pageof 21
Photochemistry and Photobiology|December 30, 2004
Effects of ultraviolet B exposure on the expression of proliferating cell nuclear antigen in murine skinJulian O Moore, Sapna R Palep, Rao N Saladi, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)Andrew Blauvelt, Kim A Papp, Mark G Lebwohl, et al.
Archives of Dermatological Research|August 20, 2018
Efficacy and safety of secukinumab treatment in adults with extensive alopecia areataEmma Guttman-Yassky, John K Nia, Peter W Hashim, et al.
Journal of the American Academy of Dermatology|April 19, 2011
Psoriasis in the elderly: from the Medical Board of the National Psoriasis FoundationIvan S Grozdev, Abby S Van Voorhees, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Journal of the American Academy of Dermatology|October 9, 2009
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis FoundationAmylynne J Frankel, Abby S Van Voorhees, Sylvia Hsu, et al.
Dermatology (Basel, Switzerland)|February 16, 2023
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis FlaresSiew Eng Choon, Mark G Lebwohl, Hamida Turki, et al.
Journal of the American Academy of Dermatology|April 4, 2018
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trialsLinda Stein Gold, Mark G Lebwohl, Jeffrey L Sugarman, et al.
Clinical and Experimental Dermatology|August 14, 2024
Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims dataAndreas Pinter, Ahmed M Soliman, Karina C Manz, et al.
Journal of the American Academy of Dermatology|September 30, 2019
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Pageof 21